TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02535351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sunitinib or pazopanib
Description: First-line treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib or pazopanib
Description: First-line treatment
Study: NCT00519714

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1-Methylnicotinamide (1-MNA)
Description: Following a 6-8-week placebo and dietary-controlled baseline period, 195 men and women will be randomized to receive placebo, 30 mg MNA or 90 mg MNA three times daily for twelve weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1-Methylnicotinamide (1-MNA)
Description: Following a 6-8-week placebo and dietary-controlled baseline period, 195 men and women will be randomized to receive placebo, 30 mg MNA or 90 mg MNA three times daily for twelve weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01929564

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beneforte broccoli
Description: Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Parthenon Broccoli
Description: Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
Study: NCT02997397

Intervention type: PROCEDURE
Intervention: tourniquet(+)
Description: A novel atraumatic tourniquet technique, applied via placing a vascular clamp widely on both the infundibulopelvic ligament and uterine arteries.

Intervention type: PROCEDURE
Intervention: tourniquet(-)
Study: NCT02535351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy
Description: Cytoreductive nephrectomy and first-line treatment
Study: NCT02930161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Runihol
Description: Composition of Runihol®:~One tablet contains:~Active ingredients: succinic acid - 0.250 g; Riboxinum (inosine) - 0.100 g; taurine - 0.050 g; Methionine - 0.050 g Excipients - 0.184 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80.~Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Runihol
Description: Composition of Runihol®:~One tablet contains:~Active ingredients: succinic acid - 0.250 g; Riboxinum (inosine) - 0.100 g; taurine - 0.050 g; Methionine - 0.050 g Excipients - 0.184 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80.~Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The composition of the drug in one tablet:~Active substance: None. The tablet core - 0.634 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80.~Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate.~Tablet weight enteric coated - 0.695 g
Study: NCT03231761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Service user testimonial videos
Description: Service users describe their personal experiences receiving care for depression or psychosis and the impact of the treatment on their quality of life
Study: NCT00840242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Description: 8-12 pieces per day, maximum 24 daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gum
Description: 8-12 pieces per day, maximum 24 daily
Study: NCT05138484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: experimental group 10% mouthwash of M. sylvestris extract
Description: To each patient was delivering a 150 ml bottle with the corresponding mouthwash. The indications for posology were: rinse with 10 ml of mouthwash for 1 minute in the mouth, every 12 hours for 7 days. To the follow-up of the intervention, was made telephone calls at least once a day to remember the rinse.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: experimental group 10% mouthwash of M. sylvestris extract
Description: To each patient was delivering a 150 ml bottle with the corresponding mouthwash. The indications for posology were: rinse with 10 ml of mouthwash for 1 minute in the mouth, every 12 hours for 7 days. To the follow-up of the intervention, was made telephone calls at least once a day to remember the rinse.
Study: NCT00840242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine inhaler
Description: 6-12 cartridges per day, maximum 12 daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhaler
Description: 6-12 cartridges per day, maximum 12 daily
Study: NCT02406209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS2
Description: NS2 ophthalmic drops (0.5%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS2
Description: NS2 ophthalmic drops (0.5%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate ophthalmic suspension (1%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate ophthalmic suspension (1%)
Study: NCT02330419

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Study: NCT02099435

Intervention type: DEVICE
Intervention: Hemospray
Description: The Hemospray™ device comes in a 7F kit and a 10F kit. Each kit includes two 220 cm Teflon application catheters, a handle with CO2 cartridge and a syringe containing approximately 20 g of the Hemospray™ material. Hemospray™ is a proprietary inorganic mineral powder that acts as a mechanical barrier when sprayed over a bleeding lesion and the surrounding mucosa.
Study: NCT02174705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Sucrose 24% orally prior to vaccine injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotavirus
Description: Rotavirus vaccine orally prior to vaccine injections
Study: NCT01884012

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: long term oxygen therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: long term oxygen therapy
Study: NCT00507650

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fluid intervention
Description: Volume of fluid prescribed by physician or provider/day X 5 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fluid intervention plus 10 ml/kg/day
Description: Fluid volume and type prescribed by physician or provider plus 10 ml/kg/day X 5 days.
Study: NCT01593280

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAP catheter
Description: dosed with 20ml of Ropivacaine 0.5% at that time. Double lumen pump containing 700 ml of the Ropivacaine 0.2% will be attached to the TAP catheters in the recovery room. The time that this occurs will be recorded in the eMAR. The catheters will run at 7cc/hr/side for 50 hrs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine
Description: 0.3 mg
Study: NCT03084757

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: research of druggable molecular alterations on tumor biopsy
Description: The study will run in 2 steps. Before starting a new treatment, patients with advanced cancer will undergo a tumor biopsy of a metastatic site in order to perform molecular analyses seeking for druggable molecular alterations
Study: NCT01680653

Intervention type: DRUG
Group type: OTHER
Intervention: Mini-glucagon
Description: Mini dose glucagon given for glucose \<70 mg/dl at a dose of 1unit/year of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mini-glucagon
Description: Mini dose glucagon given for glucose \<70 mg/dl at a dose of 1unit/year of age

Intervention type: DEVICE
Group type: OTHER
Intervention: Remote monitoring
Description: Provides real-time continuous glucose monitoring
Study: NCT03231761

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mhGAP didactic video
Description: Video with a narrated slide presentation describing diagnosis and treatment of depression and psychosis
Study: NCT01876771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177]Lu-DOTA-TATE
Description: Peptide receptor radionuclide therapy (PPRT)
Study: NCT01680653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Description: Provides real-time continuous glucose monitoring

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Carbohydrates
Description: 16 grams of carbohydrate

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Carbohydrates
Description: 16 grams of carbohydrate
Study: NCT01172964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flucytosine
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gene therapy
Description: Injected at the time of the surgery to resect the tumor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-Tesla magnetic resonance imaging
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Surgery to resect the tumor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E. coli CD-expressing genetically modified neural stem cells
Description: Injected at the time of the surgery to resect the tumor
Study: NCT02360475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine GSK3003895A (formulation 1)
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine GSK3003898A (formulation 2)
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine GSK3003899A (formulation 3)
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
Study: NCT01904903

Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab
Description: HER2 therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Pertuzumab
Description: HER2 therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Ado Trastuzumab Emtansine
Description: HER2 therapy
Study: NCT04089345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: All patients will receive intravenously (IV) ustekinumab \~6mg/kg at baseline and subcutaneously (SC) ustekinumab 90mg every 8 weeks thereafter until Week 48.
Study: NCT04027075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qlarity app users
Description: Use of the Qlarity app involves completing 12 modules and 12 practice sessions over 30 days.
Study: NCT04136275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-37 T cells
Description: CAR-37 is an investigational treatment that uses the participant own immune cells, called T cells, to try to kill the cancerous cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-37 T cells
Description: CAR-37 is an investigational treatment that uses the participant own immune cells, called T cells, to try to kill the cancerous cells
Study: NCT04048798

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen therapy via HFNC
Description: Oxygen treatment will be applied to the patients via HFNC before and after surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen therapy via face mask
Description: Oxygen treatment will be applied to the patients via face mask before and after surgery
Study: NCT03719118

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: genotyping for three genes (TPMT, NUDT15 and FTO)
Description: Patients who carry any heterozygotic variants receive 50 mg AZA or 25 mg 6-mercaptopurine (6-MP), while those who have any homozygotic variants are recommended to take other alternative drugs instead of thiopurines

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-genotyping
Description: Patients receive standard doses of thiopurines based on the conventional regimen without pretreatment genotyping. Conventional regimen starts with 50 mg of AZA, then the dose is increased by 25 mg in every 1-2 weeks to 2.0-2.5 mg/kg along with regular monitoring of general blood tests including WBC counts.
Study: NCT00817336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D Serine
Description: 60 mg/kg/day
Study: NCT03250351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization group
Description: See arm/group descriptions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: See arm/group descriptions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: See arm/group descriptions
Study: NCT00556374

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered as a subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-steroidal aromatase inhibitor therapy
Description: An approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-steroidal aromatase inhibitor therapy
Description: An approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: 5 mg zoledronic acid administered at a constant infusion rate

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care (SoC) as recommended by the treating physician, depending on individual factors such as bone density, lifestyle recommendations by the Investigator such as diet, physical activities and sun exposure, as well as local treatment standards.
Study: NCT00478699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel/Cisplatin control
Description: Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 day 1, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin
Description: Gemcitabine 1250 mg/m2, day 1 and 8 and cisplatin 75 mg/m2 day 1, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel/Cisplatin
Description: Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
Study: NCT03053427

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil
Description: Oral administration
Study: NCT00817336

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT02299427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dog safety
Description: use of dog safety website at home for about 2 weeks
Study: NCT06082882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education will be delivered in person in a group education setting or individually by phone. Group education will include a \~1-hour breast and cervical cancer prevention education session delivered with the support of electronic presentations (e.g. PowerPoint presentation ) which will include updated prevention recommendations, such as HPV vaccination recommendations for young adults. For phone education, trained project staff or CHWs will deliver telephone-based education as an alternative to group education sessions for women who missed a scheduled session twice (education materials would be printed and mailed).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education will be delivered in person in a group education setting or individually by phone. Group education will include a \~1-hour breast and cervical cancer prevention education session delivered with the support of electronic presentations (e.g. PowerPoint presentation ) which will include updated prevention recommendations, such as HPV vaccination recommendations for young adults. For phone education, trained project staff or CHWs will deliver telephone-based education as an alternative to group education sessions for women who missed a scheduled session twice (education materials would be printed and mailed).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education will be delivered in person in a group education setting or individually by phone. Group education will include a \~1-hour breast and cervical cancer prevention education session delivered with the support of electronic presentations (e.g. PowerPoint presentation ) which will include updated prevention recommendations, such as HPV vaccination recommendations for young adults. For phone education, trained project staff or CHWs will deliver telephone-based education as an alternative to group education sessions for women who missed a scheduled session twice (education materials would be printed and mailed).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation to clinic
Description: Continue telephone based navigation tailored to participants' barriers using the SEMM Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation to clinic
Description: Continue telephone based navigation tailored to participants' barriers using the SEMM Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation to clinic
Description: Continue telephone based navigation tailored to participants' barriers using the SEMM Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.
Study: NCT03337594

Intervention type: DRUG
Intervention: Pre-operative MRI with Dotarem
Description: Dotarem® (gadoterate meglumine - Guerbet)

Intervention type: DRUG
Intervention: Pre-operative MRI with MultiHance
Description: MultiHance® (gadobenate dimeglumine - Bracco)

Intervention type: PROCEDURE
Intervention: Surgery
Description: Cardiac surgery
Study: NCT02299427

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: transportation safety
Description: use of transportation safety website at home for about 2 weeks
Study: NCT03455218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: 20 ppm of Nitric Oxide gas delivered to the oxygenator for the duration of cardiopulmonary bypass

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: INOmax device connected to oxygenator, but no gas is delivered

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INOmax
Description: All patients will have the INOmax device connected to the oxygenator

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: INOmax
Description: All patients will have the INOmax device connected to the oxygenator
Study: NCT00841477

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis B vaccine 3 dose schedule (0,1,2 month)
Description: hepatitis B (HB) vaccine: Engerix-B (GlaxoSmithKline) (20 µg/dose) accelerated HB vaccine schedule (0,1,2 month),vs, standard HB vaccine schedule (0,1,6 m)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis B vaccine 3 dose schedule (0,1,2 month)
Description: hepatitis B (HB) vaccine: Engerix-B (GlaxoSmithKline) (20 µg/dose) accelerated HB vaccine schedule (0,1,2 month),vs, standard HB vaccine schedule (0,1,6 m)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HBV Vaccination Self-Efficacy Intervention
Description: HB Vaccination Intervention consists of 4 sessions - Sessions 1, 2: at screening and enrollment after intake, vs regular risk reduction education Sessions 3, 4: coincide with the vaccination schedule ions 4 before 3rd dose

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HBV Vaccination Self-Efficacy Intervention
Description: HB Vaccination Intervention consists of 4 sessions - Sessions 1, 2: at screening and enrollment after intake, vs regular risk reduction education Sessions 3, 4: coincide with the vaccination schedule ions 4 before 3rd dose
Study: NCT02414555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vasopressor
Description: Patients receive oesophageal doppler-based hemodynamic support either with fluid or with vasopressor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vasopressor
Description: Patients receive oesophageal doppler-based hemodynamic support either with fluid or with vasopressor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluid bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluid bolus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oesophagus doppler (CardioQ)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oesophagus doppler (CardioQ)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: arterial cannulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: arterial cannulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous peripheral line insertion (17 gauge)
Description: for fluid bolus administration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous peripheral line insertion (17 gauge)
Description: for fluid bolus administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elo-Mel Isoton (balanced acetat-based infusate)
Study: NCT02053064

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SAF-301
Study: NCT04069429

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computerized Tomography scan
Description: imaging scan from a person's eyes to their thighs